Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WAYNE R KOTZKER

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1124120019
CMS profile
278445
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$70,556.02

179 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WAYNE R KOTZKER

NPI 1124120019 · CMS profile ID 278445

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124120019?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WAYNE R KOTZKER, NPI 1124120019, CMS profile ID 278445. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124120019?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). WAYNE R KOTZKER, NPI 1124120019, CMS profile ID 278445. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124120019?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
WAYNE R KOTZKER, NPI 1124120019, CMS profile ID 278445, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1124120019?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

179 matching records · $70,556.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 179 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 179.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vifor Pharma, Inc. $16.5107/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896756973 CMS
Bayer HealthCare Pharmaceuticals Inc. $225.8707/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930028565 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.9107/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930173379 CMS
Bayer HealthCare Pharmaceuticals Inc. $55.4807/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930214477 CMS
Bayer HealthCare Pharmaceuticals Inc. $2,676.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930190589 CMS
Bayer HealthCare Pharmaceuticals Inc. $3,122.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930199205 CMS
AstraZeneca Pharmaceuticals LP $15.0006/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914655211 CMS
AstraZeneca Pharmaceuticals LP $125.0006/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914865417 CMS
Vifor Pharma, Inc. $15.7906/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896756971 CMS
Bayer HealthCare Pharmaceuticals Inc. $892.0006/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930064917 CMS
Bayer HealthCare Pharmaceuticals Inc. $110.1506/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930137453 CMS
Horizon Therapeutics plc $19.5606/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937646611 CMS
Horizon Therapeutics plc $12.0606/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937646613 CMS
Amgen Inc. $5.5006/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940047949 CMS
Bayer HealthCare Pharmaceuticals Inc. $233.9806/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929934369 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.0006/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930100499 CMS
Bayer HealthCare Pharmaceuticals Inc. $175.1806/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930260835 CMS
Bayer HealthCare Pharmaceuticals Inc. $72.7106/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930078883 CMS
Bayer HealthCare Pharmaceuticals Inc. $95.8506/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930075217 CMS
Novo Nordisk Inc $18.6606/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899393299 CMS
Amgen Inc. $15.1306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940047945 CMS
Amgen Inc. $8.6306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940047947 CMS
Bayer HealthCare Pharmaceuticals Inc. $62.5006/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929952713 CMS
AstraZeneca Pharmaceuticals LP $12.9006/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915043987 CMS
AstraZeneca Pharmaceuticals LP $842.5006/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915554385 CMS
AstraZeneca Pharmaceuticals LP $14.0105/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915820819 CMS
Bayer HealthCare Pharmaceuticals Inc. $892.0005/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929974881 CMS
AstraZeneca Pharmaceuticals LP $1,350.0005/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915760105 CMS
Bayer HealthCare Pharmaceuticals Inc. $2,676.0005/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930178749 CMS
Horizon Therapeutics plc $7.1205/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937646609 CMS
Horizon Therapeutics plc $16.4405/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937646607 CMS
Bayer HealthCare Pharmaceuticals Inc. $93.2405/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930254647 CMS
AstraZeneca Pharmaceuticals LP $122.5505/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914936299 CMS
Otsuka America Pharmaceutical, Inc. $2.6705/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929302783 CMS
Otsuka America Pharmaceutical, Inc. $9.5305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929302785 CMS
Amgen Inc. $9.3605/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940047941 CMS
Amgen Inc. $7.4905/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940047943 CMS
AstraZeneca Pharmaceuticals LP $18.6505/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914978071 CMS
Bayer HealthCare Pharmaceuticals Inc. $2.5705/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929881059 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.4105/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930009737 CMS
Novo Nordisk Inc $15.3205/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899393291 CMS
Bayer HealthCare Pharmaceuticals Inc. $722.0004/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929945519 CMS
Fresenius USA Marketing, Inc. $18.1704/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954574015 CMS
Horizon Therapeutics plc $6.8704/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937646603 CMS
Horizon Therapeutics plc $15.0504/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937646605 CMS
Amgen Inc. $19.8204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940047953 CMS
Amgen Inc. $1.8204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940047955 CMS
AstraZeneca Pharmaceuticals LP $21.7004/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915423215 CMS
Bayer HealthCare Pharmaceuticals Inc. $18.1704/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930120493 CMS
AstraZeneca Pharmaceuticals LP $17.2204/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915548313 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,359.14 102
PY2020 $17,933.60 80
PY2021 $16,913.23 107
PY2022 $70,556.02 179
PY2023 $95,136.68 160
PY2024 $111,709.85 225
PY2025 $138,459.65 265

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $468,359.95 22
PY2024 Principal investigator $286,639.41 30
PY2023 Principal investigator $281,266.78 22
PY2022 Principal investigator $849,755.87 42
PY2021 Principal investigator $431,095.10 74
PY2020 Principal investigator $276,875.84 126
PY2019 Recipient $912.25 9
PY2019 Principal investigator $315,525.57 111

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,314.67 12/23/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414924
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $10.00 12/03/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411500
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,075.75 11/24/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225415300
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,920.83 10/28/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413966
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,600.00 09/25/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414628
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,661.78 08/22/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413765
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $800.00 08/11/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413707
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,393.75 07/24/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413094
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,725.22 07/03/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412850
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,511.00 06/23/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225407250
Principal investigator 1 AstraZeneca Pharmaceuticals LP $233,835.00 06/11/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185551453
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,480.72 05/30/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412788
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,297.31 05/05/2025 Non-covered Recipient Entity
Panoramic Science Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412754
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,761.08 03/27/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225403663
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $434.10 03/06/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225407166
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,228.00 02/21/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225406746
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $120.00 02/07/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225406744
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $120.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411768
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $338.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411798
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,500.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411820
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,800.00 01/09/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225403407
Principal investigator 1 AstraZeneca Pharmaceuticals LP $193,432.74 01/03/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185551455